InflaRx announced enrollment of the first patient in its Phase 2b study with IFX-1, an anti-human complement factor
C5a antibody, in patients suffering from moderate or severe Hidradenitis Suppurativa, or HS.
Objective: To evaluate the complement factor
3 levels in children with hepatitis A.
The open IND will allow InflaRx to conduct a phase IIb study to determine efficacy and safety of IFX-1, a first-in-class anti-human complement factor
C5a antibody, in patients with moderate or severe Hidradenitis Suppurativa (HS), a painful, chronic, and debilitating inflammatory skin disease.
9,796,741, entitled "Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Complement Mediated Disorders," has been granted with claims to compositions of matter for ACH-4471 and additional compounds that inhibit complement factor
D activity, a key mediator in the complement alternative pathway (AP).
According to the contract, Grid Therapeutics has acquired the exclusive rights to all intellectual property, including relevant patents, related to Complement Factor
H antibodies as a cancer therapy, and diagnostics around Complement Factor
sup] In 2005, four groups identified a genetic polymorphism in complement factor
H which was associated with an increased risk of developing AMD.
B and adipsin are essential for the formation of C3a from C3, leading to the production of ASP.
H polymorphism in age-related macular degeneration.
The pathogenesis of aHUS is mainly associated with gene mutations in complement factor
H, complement factor
I, and membrane cofactor protein (MCP).
Inflammation is involved in many types of pathologies, from AK and Bowen's disease (BD) to cutaneous SCC (cSCC) and other kind of cancers; thus the involvement of inflammatory markers, such as the complement factor
H (CFH) and FHL-1 (factor H-like protein-1) in the development of cSCC has attracted an increasing interest .
We look forward to him continuing his work to address the needs of patients by stewarding Achillion's expanding portfolio of complement factor
D inhibitors including ACH-4471 which is poised to enter clinical development.
HLA (human leukocyte antigen), reninangiotensin system-related genes (RAS), complement factor
immunoglobulins and cytokines, T-cell receptor alpha or beta chain genes are related to the predisposition and progression of the IgAN disease.